Literature DB >> 29371780

Cinderella in Serum Protein Electrophoresis.

Srinivas Narasimhachar Chakravarthy1, Satish Ramanathan1, Smitha Menon1, Vijayakumar Valappil1, Mathivanan Durairaj1, Jayarani Arokia1.   

Abstract

Paraproteinemia is characterised by clonal proliferation of plasma cells. A common laboratory finding in paraproteinemia being a monoclonal peak in serum protein electrophoresis (M band). But there are factors which produce a peak similar to M spike in serum protein electrophoresis and these factors are known as pseudoparaproteins. This case report discusses a rare cause of pseudo M spike in a known case of autoimmune hemolytic anaemia due to administration of drug-Rituximab, a monoclonal antibody by itself.

Entities:  

Keywords:  M spike; Paraproteins; Rituximab

Year:  2017        PMID: 29371780      PMCID: PMC5766462          DOI: 10.1007/s12291-017-0643-8

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  7 in total

1.  The incidence and significance of pseudoparaproteins in a community hospital.

Authors:  S L Strobel
Journal:  Ann Clin Lab Sci       Date:  2000-07       Impact factor: 1.256

2.  Interference of monoclonal antibody therapies with serum protein electrophoresis tests.

Authors:  Christopher R McCudden; Peter M Voorhees; Shirley A Hainsworth; Herbert C Whinna; John F Chapman; Catherine A Hammett-Stabler; Monte S Willis
Journal:  Clin Chem       Date:  2010-10-12       Impact factor: 8.327

3.  Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins.

Authors:  Janneke Ruinemans-Koerts; Cyriel Verkroost; Yvonne Schmidt-Hieltjes; Cees Wiegers; Joyce Curvers; Marc Thelen; Matthijs van Luin
Journal:  Clin Chem Lab Med       Date:  2014-11       Impact factor: 3.694

4.  Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2012-01       Impact factor: 10.047

Review 5.  Management of paraproteinaemia.

Authors:  Lucy Cook; Donald H C Macdonald
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

Review 6.  Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.

Authors:  M D Pescovitz
Journal:  Am J Transplant       Date:  2006-05       Impact factor: 8.086

7.  Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.

Authors:  Christopher McCudden; Amy E Axel; Dominique Slaets; Thomas Dejoie; Pamela L Clemens; Sandy Frans; Jaime Bald; Torben Plesner; Joannes F M Jacobs; Niels W C J van de Donk; Philippe Moreau; Jordan M Schecter; Tahamtan Ahmadi; A Kate Sasser
Journal:  Clin Chem Lab Med       Date:  2016-06-01       Impact factor: 3.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.